Affiliation:
1. University School of Biotechnology, Guru Gobind Singh Indraprastha University, New Delhi, India.
2. Department of Pathology, Govind Ballabh Pant Hospital, New Delhi, India.
Abstract
Introduction Microsatellite instability (MSI), referred to as variations at microsatellite loci, at mismatch repair (MMR) genes leads to the formation of an aberrant MMR system that fails to rectify errors occurring during DNA replication. MMR deficiency can be assessed by immunohistochemical analysis of the expression of mismatch repair proteins in the target tissues.
Methods We investigated the expression of four key MMR proteins (MLH1, MSH2, MSH6, and PMS2) in formalin-fixed paraffin-embedded (FFPE) tumor and normal tissues obtained from thirty gastric cancer (GC) patients. The association of clinicopathological features with MMR status was also analyzed.
Results A total of 12 (40%) GC patients exhibited loss of expression of MMR proteins, including loss of MLH1 and PMS2 in 3 cases and loss of MSH2 and MSH6 in 4 cases. Univariate analysis showed an association of loss of MMR protein expression with moderately differentiated GC. However, there was no statistically significant association between loss of MMR protein expression with gender, tumor location, depth of invasion, lymph node metastasis, WHO classification, lympho-vascular invasion, and infection with H. pylori.
Conclusion Our results implicate the role of mismatch repair proteins in gastric tumorigenesis. The MMR protein status is an important aspect of tumorigenesis and can be prescribed for the screening of GC.
Publisher
Asian Medical Press Limited
Reference29 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018, https://doi.org/10.3322/caac.21492. Epub ahead of print.
2. De Vita F, Di Martino N, Fabozzi A, Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V, Sforza V, Marano L et al: Clinical management of advanced gastric cancer: the role of new molecular drugs. World J Gastroenterol 2014, 20(40):14537-14558.
3. Dikshit R, Gupta PC, Ramasundarahettige C, Gajalakshmi V, Aleksandrowicz L, Badwe R, Kumar R, Roy S, Suraweera W, Bray F et al: Cancer mortality in India: a nationally representative survey. Lancet 2012, 379(9828):1807-1816.
4. Kalyani R, Das S, Kumar ML: Pattern of cancer in adolescent and young adults--a ten year study in India. Asian Pac J Cancer Prev 2010, 11(3):655-659.
5. Cheng XJ, Lin JC, Tu SP: Etiology and Prevention of Gastric Cancer. Gastrointest Tumors 2016, 3(1):25-36.